Herb–drug interaction studies of herbs used in treatment of cardiovascular disorders—A narrative review of preclinical and clinical studies

2020 ◽  
Vol 34 (5) ◽  
pp. 1008-1026 ◽  
Author(s):  
Aaftab S. Shaikh ◽  
Asha B. Thomas ◽  
Sohan S. Chitlange
Keyword(s):  
Drug Interaction ◽  
Clinical Studies ◽  
Narrative Review ◽  
Cardiovascular Disorders ◽  
Interaction Studies ◽  
Preclinical And Clinical Studies

scholarly journals Treatment of DM2 to-day. Should we change priorities? Conclusions based on recent clinical studies

2009 ◽  
Vol 12 (4) ◽  
pp. 108-113
Author(s):  
Aleksey Vadimovich Zilov
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Drug Interaction ◽  
Clinical Studies ◽  
Close Association ◽  
Cardiovascular Disorders ◽  
Analysis Of Results ◽  
Number Of Publications ◽  
Sulphonylurea Derivatives ◽  
Multifactor Approach

This work is devoted to the analysis of results of recent clinical studies. It is argued that the absence of close association between normalized glycemiaand reduced incidence of cardiovascular disorders may be due to both relatively short duration of observations and possible effect of co-factors (e.g. hypoglycemia/drug interaction, etc.). Some results suggest the necessity of multifactor approach to the treatment of DM2 especially for the reductionof cardiovascular mortality or prevention of vascular catastrophes. Sulphonylurea derivatives are regarded as putative risk factors of hypoglycemiaor vascular disorders. A number of publications are reviewed in which glibenclamide was shown to be safe in terms of risk of myocardial infarction.

Gastrointestinal abnormalities and Nigella sativa: A narrative review of preclinical and clinical studies

2022 ◽  
pp. 355-386
Author(s):  
Foziyah Zakir ◽  
Harshita Mishra ◽  
Mohammad Azharuddin ◽  
M. Aamir Mirza ◽  
Geeta Aggarwal ◽  
...  
Keyword(s):  
Clinical Studies ◽  
Nigella Sativa ◽  
Narrative Review ◽  
Preclinical And Clinical Studies ◽  
Gastrointestinal Abnormalities

Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies

2019 ◽  
Vol 20 (2) ◽  
pp. 114-123 ◽  
Author(s):  
Panjasaram Naidoo ◽  
Manoranjenni Chetty
Keyword(s):  
Sex Differences ◽  
Drug Interaction ◽  
Drug Interactions ◽  
Clinical Studies ◽  
Qt Prolongation ◽  
Equal Proportion ◽  
Anecdotal Evidence ◽  
Interaction Studies ◽  
Males And Females ◽  
General Guidance

Background: Anecdotal evidence suggests that there may be sex differences in Drug-drug Interactions (DDI) involving specific drugs. Regulators have provided general guidance for the inclusion of females in clinical studies. Some clinical studies have reported sex differences in the Pharmacokinetics (PK) of CYP3A4 substrates, suggesting that DDI involving CYP3A4 substrates could potentially show sex differences. Objective: The aim of this review was to investigate whether recent prospective DDI studies have included both sexes and whether there was evidence for the presence or absence of sex differences with the DDIs. Methods: The relevant details from 156 drug interaction studies within 124 papers were extracted and evaluated. Results: Only eight studies (five papers) compared the outcome of the DDI between males and females. The majority of the studies had only male volunteers. Five studies had females only while 60 had males only, with 7.7% of the studies having an equal proportion of both sexes. Surprisingly, four studies did not specify the sex of the subjects. : Based on the limited number of studies comparing males and females, no specific trends or conclusions were evident. Sex differences in the interaction were reported between ketoconazole and midazolam as well as clarithromycin and midazolam. However, no sex difference was observed with the interaction between clarithromycin and triazolam or erythromycin and triazolam. No sex-related PK differences were observed with the interaction between ketoconazole and domperidone, although sex-related differences in QT prolongation were observed. Conclusion: This review has shown that only limited progress had been made with the inclusion of both sexes in DDI studies.

Drug interaction studies of esomeprazole with amoxicillin and clarithromycin

2001 ◽  
Vol 120 (5) ◽  
pp. A581-A581
Author(s):  
T ANDERSSON ◽  
L ASTRAZENECA ◽  
K ROHSS ◽  
M HASSANALIN
Keyword(s):  
Drug Interaction ◽  
Interaction Studies
Sign in / Sign up

Export Citation Format

Share Document